TP53 and lung cancer: Vikhanskaya evaluated the effect of six TP53 hotspot mutations (R175H, G245S, R248W, R249S, R273H, and R282W), in conjunction with the codon 72 polymorphism, on various anticancer drugs, either alone or in combination in laboratory generated isogenic lung cancer cell lines (33).